PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World…
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it…
NMQF Releases Report that 56% of People of Color Live in Carcinogenic Environments; Announce Public-Private Collaboration to Address ProblemWashington, D.C.--(Newsfile…
Providing Real-World Data for Life Science and Medtech AdvancementsPALO ALTO, CA / ACCESSWIRE / January 24, 2024 / Lynx.MD, a…
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS…
Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine…
- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -…
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma…
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted…